|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
14 September 2015 |
|
Main ID: |
NCT00816504 |
|
Date of registration:
|
31/12/2008 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
|
|
Scientific title:
|
Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5 |
|
Date of first enrolment:
|
December 2008 |
|
Target sample size:
|
0 |
|
Recruitment status: |
Withdrawn |
|
URL:
|
https://clinicaltrials.gov/show/NCT00816504 |
|
Study type:
|
Interventional |
|
Study design:
|
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 1
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Howard Trachtman, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Schneider Children's Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Primary FSGS
- CKD Stage 5
- Resistance to steroids and another immunosuppressive medication
Exclusion Criteria:
- Secondary FSGS
Age minimum:
2 Years
Age maximum:
60 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Focal Segmental Glomerulosclerosis
|
|
Intervention(s)
|
|
Drug: Galactose
|
|
Primary Outcome(s)
|
|
Reduction in FSGS permeability factor
[Time Frame: 28 days]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|